APA (7th ed.) Citation

C, P., K, K., NB, A., SD, B., & JH, H. (2026). Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer. Therapeutic advances in drug safety, 17, 20420986251414588. https://doi.org/10.1177/20420986251414588

Chicago Style (17th ed.) Citation

C, Park, Kim K, Abifaraj NB, Bryant SD, and Heo JH. "Integration of Pre‑existing Cardiovascular Comorbidity into CDK4/6 Inhibitor Selection for Breast Cancer." Therapeutic Advances in Drug Safety 17 (2026): 20420986251414588. https://doi.org/10.1177/20420986251414588.

MLA (9th ed.) Citation

C, Park, et al. "Integration of Pre‑existing Cardiovascular Comorbidity into CDK4/6 Inhibitor Selection for Breast Cancer." Therapeutic Advances in Drug Safety, vol. 17, 2026, p. 20420986251414588, https://doi.org/10.1177/20420986251414588.